Vanguard Group’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-242,940
| Closed | -$9.65M | – | 4130 |
|
|
2016
Q3 | $9.65M | Sell |
242,940
-96,235
| -28% | -$1.07M | ﹤0.01% | 2707 |
|
|
2016
Q2 | $4.26M | Buy |
339,175
+19,125
| +6% | +$178K | ﹤0.01% | 3061 |
|
|
2016
Q1 | $2.62M | Buy |
320,050
+4,906
| +2% | +$37K | ﹤0.01% | 3275 |
|
|
2015
Q4 | $3.17M | Buy |
315,144
+7,709
| +3% | +$80.1K | ﹤0.01% | 3208 |
|
|
2015
Q3 | $2.97M | Buy |
307,435
+45,942
| +18% | +$645K | ﹤0.01% | 3202 |
|
|
2015
Q2 | $4.51M | Buy |
261,493
+198,487
| +315% | +$2.9M | ﹤0.01% | 3065 |
|
|
2015
Q1 | $691K | Buy |
63,006
+2,576
| +4% | +$27.7K | ﹤0.01% | 3735 |
|
|
2014
Q4 | $496K | Buy |
60,430
+65
| +0.1% | +$560 | ﹤0.01% | 3728 |
|
|
2014
Q3 | $614K | Buy |
60,365
+4,299
| +8% | +$84.9K | ﹤0.01% | 3658 |
|
|
2014
Q2 | $3.43M | Buy |
56,066
+46,917
| +513% | +$2.85M | ﹤0.01% | 3022 |
|
|
2014
Q1 | $1.03M | Buy |
9,149
+7,905
| +635% | +$555K | ﹤0.01% | 3451 |
|
|
2013
Q4 | $53K | Buy |
+1,244
| New | +$58.4K | ﹤0.01% | 3877 |
|
Vanguard Group's TBRA Position: Q4 2016 in Review
Vanguard Group sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 242,940 shares — an estimated $9.65M sold.
Vanguard Group first reported a position in TBRA in Q4 2013 and held it in 12 quarters. The position peaked at $9.65M in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.
- Vanguard Group reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
- Vanguard Group sold 242,940 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $9.65M.
- Vanguard Group first reported a position in Tobira Therapeutics, Inc. Common Stock in Q4 2013 and held it in 12 quarters.
- Vanguard Group's Tobira Therapeutics, Inc. Common Stock position peaked at $9.65M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.
Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.